Revvity (PKN) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PKN Analyst Ratings

Moderate Buy

3 Buy

8 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Revvity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PKN Stock 12 Month Forecast

Average Price Target

€93.71

▲(22.95% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Revvity in the last 3 months. The average price target is €93.71 with a high forecast of €105.22 and a low forecast of €78.92. The average price target represents a 22.95% change from the last price of €76.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"69":"€69","106":"€106","78.25":"€78.3","87.5":"€87.5","96.75":"€96.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105.2219916,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€105.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.71333626875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€93.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.9164937,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€78.92</span>\n  </div></div>","useHTML":true}}],"tickPositions":[69,78.25,87.5,96.75,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.9,97.5401532,98.1803064,98.8204596,99.4606128,100.10076600000001,100.74091920000001,101.3810724,102.0212256,102.6613788,103.301532,103.9416852,104.5818384,{"y":105.2219916,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.9,96.65487202067308,96.40974404134616,96.16461606201923,95.91948808269231,95.67436010336539,95.42923212403846,95.18410414471154,94.93897616538462,94.69384818605769,94.44872020673077,94.20359222740385,93.95846424807692,{"y":93.71333626875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.9,95.51665336153847,94.13330672307693,92.7499600846154,91.36661344615385,89.98326680769232,88.59992016923077,87.21657353076924,85.83322689230769,84.44988025384616,83.06653361538461,81.68318697692308,80.29984033846154,{"y":78.9164937,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":80.905,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.699,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.956,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.318,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.749,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.095,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.465,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.692,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.858,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.202,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.98,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€105.22

Average Price Target€93.71

Lowest Price Target€78.92

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eve Burstein

Bernstein

€100.84

Hold

32.30%

Upside

Initiated

06/25/26

Revvity resumed with a Market Perform at BernsteinRevvity resumed with a Market Perform at Bernstein

Luke Sergott

Barclays

€92.07

Hold

20.79%

Upside

Reiterated

06/24/26

Barclays Remains a Hold on Revvity (RVTY)

Daniel Brennan

TD Cowen

€105.22

Buy

38.05%

Upside

Reiterated

06/18/26

Revvity Rated Buy on Improving Fundamentals and Undervaluation; $120 Price Target Reaffirmed

Michael Polark

Wolfe Research

―

Hold

―

Initiated

06/01/26

Revvity assumed with a Peer Perform at Wolfe ResearchRevvity assumed with a Peer Perform at Wolfe Research

Michael Ryskin

Bank of America Securities

―

Hold

―

Reiterated

05/14/26

Analysts Conflicted on These Healthcare Names: Cullinan Management (NASDAQ: CGEM), Humacyte (NASDAQ: HUMA) and Revvity (NYSE: RVTY)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

05/11/26

Revvity (RVTY) Receives a Hold from Guggenheim

Daniel Arias

Stifel Nicolaus

€96.45→€87.68

Hold

15.04%

Upside

Assigned

05/06/26

Revvity price target lowered to $100 from $110 at StifelRevvity price target lowered to $100 from $110 at Stifel

Casey Woodring

J.P. Morgan

€84.18→€78.92

Hold

3.54%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Option Care Health (NASDAQ: OPCH) and OnKure Therapeutics (NASDAQ: OKUR)

Evie Koslosky

Goldman Sachs

€83.3→€87.68

Hold

15.04%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Vir Biotechnology (NASDAQ: VIR) and Johnson & Johnson (NYSE: JNJ)

Catherine Ramsey Schulte

Robert W. Baird

€113.11→€102.59

Buy

34.60%

Upside

Reiterated

05/04/26

Revvity price target lowered to $125 from $129 at BairdRevvity price target lowered to $125 from $129 at Baird

Vijay Kumar

Evercore ISI

€103.47→€94.7

Buy

24.25%

Upside

Assigned

04/06/26

Revvity price target lowered to $108 from $118 at Evercore ISIRevvity price target lowered to $108 from $118 at Evercore ISI

Jack Meehan

Nephron

€78.92

Hold

3.54%

Upside

Upgraded

03/26/26

Revvity upgraded to Hold from Sell at Nephron ResearchRevvity upgraded to Hold from Sell at Nephron Research

Unknown Analyst

UBS

Not Ranked

UBS

€100.84→€105.22

Buy

38.05%

Upside

Reiterated

02/03/26

Revvity (RVTY) Receives a Buy from UBS

Brandon Couillard

Wells Fargo

€93.82→€96.45

Hold

26.55%

Upside

Reiterated

02/03/26

Wells Fargo Reaffirms Their Hold Rating on Revvity (RVTY)

Tycho Peterson

Jefferies

€87.68→€92.07

Hold

20.79%

Upside

Reiterated

02/02/26

Revvity price target raised to $105 from $100 at JefferiesRevvity price target raised to $105 from $100 at Jefferies

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eve Burstein

Bernstein

€100.84

Hold

32.30%

Upside

Initiated

06/25/26

Revvity resumed with a Market Perform at BernsteinRevvity resumed with a Market Perform at Bernstein

Luke Sergott

Barclays

€92.07

Hold

20.79%

Upside

Reiterated

06/24/26

Barclays Remains a Hold on Revvity (RVTY)

Daniel Brennan

TD Cowen

€105.22

Buy

38.05%

Upside

Reiterated

06/18/26

Revvity Rated Buy on Improving Fundamentals and Undervaluation; $120 Price Target Reaffirmed

Michael Polark

Wolfe Research

―

Hold

―

Initiated

06/01/26

Revvity assumed with a Peer Perform at Wolfe ResearchRevvity assumed with a Peer Perform at Wolfe Research

Michael Ryskin

Bank of America Securities

―

Hold

―

Reiterated

05/14/26

Analysts Conflicted on These Healthcare Names: Cullinan Management (NASDAQ: CGEM), Humacyte (NASDAQ: HUMA) and Revvity (NYSE: RVTY)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

05/11/26

Revvity (RVTY) Receives a Hold from Guggenheim

Daniel Arias

Stifel Nicolaus

€96.45→€87.68

Hold

15.04%

Upside

Assigned

05/06/26

Revvity price target lowered to $100 from $110 at StifelRevvity price target lowered to $100 from $110 at Stifel

Casey Woodring

J.P. Morgan

€84.18→€78.92

Hold

3.54%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Option Care Health (NASDAQ: OPCH) and OnKure Therapeutics (NASDAQ: OKUR)

Evie Koslosky

Goldman Sachs

€83.3→€87.68

Hold

15.04%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Vir Biotechnology (NASDAQ: VIR) and Johnson & Johnson (NYSE: JNJ)

Catherine Ramsey Schulte

Robert W. Baird

€113.11→€102.59

Buy

34.60%

Upside

Reiterated

05/04/26

Revvity price target lowered to $125 from $129 at BairdRevvity price target lowered to $125 from $129 at Baird

Vijay Kumar

Evercore ISI

€103.47→€94.7

Buy

24.25%

Upside

Assigned

04/06/26

Revvity price target lowered to $108 from $118 at Evercore ISIRevvity price target lowered to $108 from $118 at Evercore ISI

Jack Meehan

Nephron

€78.92

Hold

3.54%

Upside

Upgraded

03/26/26

Revvity upgraded to Hold from Sell at Nephron ResearchRevvity upgraded to Hold from Sell at Nephron Research

Unknown Analyst

UBS

Not Ranked

UBS

€100.84→€105.22

Buy

38.05%

Upside

Reiterated

02/03/26

Revvity (RVTY) Receives a Buy from UBS

Brandon Couillard

Wells Fargo

€93.82→€96.45

Hold

26.55%

Upside

Reiterated

02/03/26

Wells Fargo Reaffirms Their Hold Rating on Revvity (RVTY)

Tycho Peterson

Jefferies

€87.68→€92.07

Hold

20.79%

Upside

Reiterated

02/02/26

Revvity price target raised to $105 from $100 at JefferiesRevvity price target raised to $105 from $100 at Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revvity

3 Months

Catherine Ramsey SchulteRobert W. Baird

Success Rate

24/37 ratings generated profit

Average Return

+3.04%

Copying Catherine Ramsey Schulte's trades and holding each position for 3 Months would result in 64.86% of your transactions generating a profit, with an average return of +3.04% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

9/14 ratings generated profit

Average Return

+5.47%

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +5.47% per trade.

2 Years

Daniel BrennanTD Cowen

Success Rate

10/14 ratings generated profit

Average Return

+6.17%

Copying Daniel Brennan's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +6.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PKN Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PKN has received 3 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. PKN average Analyst price target in the past 3 months is 93.71.

Each month's total comprises the sum of three months' worth of ratings.

PKN Financial Forecast

PKN Earnings Forecast

Next quarter’s earnings estimate for PKN is €1.06 with a range of €1.05 to €1.08. The previous quarter’s EPS was €0.91. PKN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PKN has Performed in-line its overall industry.

PKN Sales Forecast

Next quarter’s sales forecast for PKN is €617.89M with a range of €611.40M to €622.82M. The previous quarter’s sales results were €624.68M. PKN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PKN has Performed in-line its overall industry.

PKN Stock Forecast FAQ

What is DE:PKN’s average 12-month price target, according to analysts?

Based on analyst ratings, Revvity’s 12-month average price target is 93.71.

What is DE:PKN’s upside potential, based on the analysts’ average price target?

Revvity has 22.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Revvity a Buy, Sell or Hold?

Revvity has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 8 hold ratings and 0 sell ratings.

What is Revvity’s share price target?

The average share price target for Revvity is 93.71. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €105.22 ,and the lowest forecast is €78.92. The average share price target represents 22.95% Increase from the current price of €76.22.

What do analysts say about Revvity?

Revvity’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Revvity?

To buy shares of DE:PKN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Revvity (PKN) Stock Forecast & Price Target

PKN Analyst Ratings

PKN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Revvity

PKN Analyst Recommendation Trends

PKN Financial Forecast

PKN Earnings Forecast

PKN Sales Forecast

PKN Stock Forecast FAQ

Detailed List of Analyst Forecasts